November 2024 – Page 5

Bristol Myers Squibb Announces Additional Layoffs in New Jersey Amid Cost-Cutting Efforts

5 months ago talkbio0Tagged cost-cutting, Drug Industry, Myers, New Jersey, squibb

Bristol Myers Squibb, layoffs, New Jersey, cost-cutting, pharmaceutical industry

Adcendo Secures $135 Million Funding for Antibody-Drug Conjugate Pipeline

5 months ago talkbio0Tagged ADC, Adcendo, Antibody-Drug, Holdings, pipeline, therapeutic autologous dendritic cells

Adcendo, Novo Holdings, ADC pipeline, funding, biotech, antibody-drug conjugate

Trump Nominates Renowned Surgeon Martin Makary as FDA Commissioner

5 months ago talkbio0Tagged Commissioner, Donald Trump, Hopkins, Johns, Makary, Martin, nomination, Surgeon, United States Food and Drug Administration

Martin Makary, FDA Commissioner, Donald Trump, Johns Hopkins, Surgeon, Nomination

Biohaven’s Taldefgrobep Alfa Misses Primary Endpoint in Phase 3 SMA Trial, Eyes FDA Discussions and Obesity Indication

5 months ago talkbio0Tagged Discussion (procedure), Indication of (contextual qualifier), Obesity, Phase 3 trial, Spinal Muscular Atrophy, Talditercept alfa, United States Food and Drug Administration

Biohaven, Taldefgrobep Alfa, Spinal Muscular Atrophy (SMA), Phase 3 Trial, FDA Discussions, Obesity Indication

Merck Advances with Winrevair: Positive Phase III Results in Severe Pulmonary Arterial Hypertension (PAH) Study

5 months ago talkbio0Tagged Cardiovascular system, Merck, Morbidity - disease rate, Mortality Vital Statistics, PAH, Phase III, Pulmonary arterial hypertension, Winrevair, ZENITH study

Merck, Winrevair, PAH, Phase III, ZENITH study, pulmonary arterial hypertension, cardiovascular drug, morbidity, mortality

Advancements in Hematology: Shaping the Future of Blood Disorder Diagnosis and Treatment

5 months ago talkbio0Tagged Anemia, Sickle Cell, Clinical Practice Guideline, gene therapy, Hematological Disease, Hematology (discipline), Improvement, Quality

Hematology, Blood Disorders, Sickle Cell Disease, Gene Therapy, Clinical Guidelines, Quality Improvement

Biopharma Industry Braces for Uncertainty Under Trump’s Second Term: Impact on Vaccines and M&A Deals

5 months ago talkbio0Tagged Biopharma Industry, Changing, FTC, Health Policy, M&A, Policy, Regulation, second, Trump 's, United States Federal Trade Commission, Vaccines

Trump’s second term, Biopharma industry, Vaccine regulation, Robert F. Kennedy Jr., M&A deals, FTC policy changes, Healthcare policy uncertainty

Nabla Bio Revolutionizes AI-Driven Protein Design with $26M Series A Funding and Major Pharmaceutical Collaborations

5 months ago talkbio0Tagged Drug Development, Funding, Generative Protein Design, Multipass Membrane, Pharmaceutical Collaborations, Proteins, Series, Therapeutic Antibodies

Generative Protein Design, AI-Driven Drug Development, Therapeutic Antibodies, Multipass Membrane Proteins, Pharmaceutical Collaborations, Series A Funding

Lexicon Pharmaceuticals Shifts Focus to Clinical Development Following Zynquista Setbacks

5 months ago talkbio0Tagged (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol, Clinical Development, lexicon, LX9211, LX9851, R&D pipeline, restructuring, United States Food and Drug Administration, Zynquista

Lexicon Pharmaceuticals, Zynquista, FDA, Clinical Development, Restructuring, R&D Pipeline, LX9211, Sotagliflozin, LX9851

AstraZeneca Addresses Safety Concerns Over Andexxa, Discontinues Opioid Use Disorder Drug

5 months ago talkbio0Tagged Andexxa, Anticoagulation Therapy, AstraZeneca, concerns, Opioid Use Disorder, Reversal, Safety, United States Food and Drug Administration

AstraZeneca, Andexxa, FDA, Safety Concerns, Anticoagulation Reversal, Opioid Use Disorder, AZD4041